Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

Apellis Pharmaceuticals Launch Update of SYFOVRE®
On October 5, 2023, Apellis Pharmaceuticals (APLS) provided an update on the launch of its product SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
About Geographic Atrophy
GA is an advanced form of age-related macular degeneration and a leading cause of blindness, impacting more than one million Americans . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.